Century Therapeutics, Inc. (IPSC)

Market Cap	420.55M +635.5%
Revenue (ttm)	109.16M +1,556.8%
Net Income	-9.58M
EPS	-0.11
Shares Out	179.72M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,248,302
Open	2.480
Previous Close	2.500
Day's Range	2.290 - 2.580
52-Week Range	0.342 - 3.040
Beta	1.71
Analysts	Strong Buy
Price Target	3.50 (+49.57%)
Earnings Date	Mar 12, 2026

About IPSC

Century Therapeutics, Inc., a biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-813, an iPSC-derived beta islet cell replacement therapy engineered with Allo-Evasion 5.0 for the treatment of type 1 diabetes. The company is also involved in the development of CNTY-308, a CD19-targeted CD4+/CD8+ CAR-iT cell therapy engineered with Allo-Evasion 5.0 as a potential treatment for B-cell-mediated autoim...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 18, 2021
• Employees: 150
• Stock Exchange: NASDAQ
• Ticker Symbol: IPSC
• Website: https://www.centurytx.com

Financial Performance

In 2025, Century Therapeutics's revenue was $109.16 million, an increase of 1556.76% compared to the previous year's $6.59 million. Losses were -$9.58 million, -92.43% less than in 2024.

Analyst Summary

According to 5 analysts, the average rating for IPSC stock is "Strong Buy." The 12-month stock price target is $3.5, which is an increase of 49.57% from the latest price.

Price Target

$3.5

(49.57% upside)

Analyst Consensus: Strong Buy